Although a randomized trial demonstrated a survival benefit of cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) over systemic chemotherapy alone, the treatment of peritoneal carcinomatosis from colorectal cancer (CRPC) is still a matter of debate. The aims of this study were to evaluate long-term outcome after CRS and IPC and to identify the prognostic factors associated with a cure.
Patients were considered cured if the disease-free survival interval lasted at least 5 years after the treatment of CRPC or its last recurrence. Patients who had died postoperatively, or from non–cancer-related deaths, or patients with a follow-up of less than 5 years since the last curative treatment were excluded from the analysis.
From 1995 to 2006, 107 patients (median age, 48 years; range, 19–67 years) underwent complete CRS, followed by IPC. Postoperative complications occurred in 50 patients (53%), including 4 postoperative deaths. After a median follow-up of 77 months (range, 60–144 months), 5-year and 10-year overall survival rates were 35% and 15%, respectively. Seventeen patients (16%) were considered cured after a disease-free interval of at least 5 years, of whom 14 never developed a recurrence. Cured patients had a significantly lower median peritoneal cancer index than noncured patients, respectively 4 (3–16) and 12 (2–36) (P = 0.0002). In multivariate analysis, a peritoneal cancer index of 10 or less was the only independent factor predicting cure.
The cure rate (16%) after complete CRS of colorectal peritoneal carcinomatosis, followed by IPC, in selected patients is close to that obtained after resection of colorectal liver metastases.
From 1995 to 2006, 107 patients underwent complete cytoreductive surgery, followed by intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. Seventeen patients (16%) were considered cured after a disease-free interval of at least 5 years. This cure rate of 16% is close to that obtained after resection of colorectal liver metastases.
Departments of *Surgical Oncology and
†Medical Oncology, Institut Gustave Roussy, Villejuif Cedex, France.
Reprints: Diane Goéré, MD, Department of Surgical Oncology, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif Cedex, France. E-mail: firstname.lastname@example.org.
Disclosure: The authors declare no conflicts of interest.